A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoformselective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1

Category Systematic review
Conference2025 ASCO Genitourinary Cancers Symposium
Year 2025
This article has no abstract
Epistemonikos ID: a49462a9a61e0e15dab6daffbb6af846fd44f73e
First added on: Jan 22, 2026